Curriculum Vitae

Name:

Dr. David Fogelson

Address:

2730 Wilshire Blvd., Suite 325
Santa Monica, California 90403
Telephone: (310) 828-5015
Fax: (310) 829-3877
E-mail: dfogelso@ucla.edu
Internet: www.davidfogelson.com

Title:

Clinical Professor, University of California at Los Angeles Department of Psychiatry and Biobehavioral Sciences

Place of Birth:

Los Angeles, CA

Education

1972 B.A. University of California at Santa Cruz, honors in Biology
1977 M.D. Harvard Medical School

Post Doctoral Training

Internships & Residencies

1977-1978 Intern in Medicine, The Faulkner Hospital, Boston, MA

1978-1979 Resident in Psychiatry, Tufts University, Court Street Veterans Administration Outpatient Clinic, Boston, MA

1979-1981 Resident in Psychiatry, The Neuropsychiatric Institute, University of California at Los Angeles

1981-1982 Fellow in Psychopharmacology, McLean Hospital, Belmont, Massachusetts, a division of Harvard Medical School

Licenses & Certification

1977 Massachusetts License Registration No. 43088

1977 Diplomate of the National Board of Medical Examiners, No. 179116

1979 California License registration No. G039149

1984 Diplomate American Board of Psychiatry and Neurology No. 25840

2014 Georgia Medical License Registration No. 72773

Hospital Appointments

1979-1979 Medical Staff Member, Braintree Hospital, Braintree, MA

1978-1979 Psychiatric Staff Member, Boston State Hospital, Boston, MA

1979-1981 Psychiatric Staff Member, Olive View Hospital, Los Angeles, CA

1981-1982 Psychiatric Staff Member, McLean Hospital, Belmont, MA

1982-1984 Medical Staff Member, Encino Hospital, Encino, CA

1982-1985 Psychiatric Staff Member, Van Nuys Hospital, Van Nuys, CA

1982-1985 Psychiatric Staff Member, Woodview Calabasas Hospital, Calabasas, CA

1986-1993 Psychiatric Staff Member, Westwood Hospital, Westwood, CA

1987-1993 Psychiatric Staff Member, St. John’s Hospital, Santa Monica, CA

1981-2009 Psychiatric Staff Member, UCLA Neuropsychiatric Hospital, Westwood, CA

Awards & Honors

1972 Graduated with Honors in Biology from the University of California at Santa Cruz

1987-1991 Member, Board of Directors, Obsessive Compulsive Foundation

1992 Distinguished Fellow American Psychiatric Association

1996-present Elected by his peers for inclusion in Best Doctors in America®

1995 Outstanding Junior Clinical Faculty Teaching Award UCLA Neuropsychiatric Institute and Hospital Residency Program

1996 Member, Scientific Advisory Board, Obsessive Compulsive Foundation of California

Major Committee Assignments

Membership In Professional Societies

1978-1993 American Association for the Advancement of Science

1979 American Psychiatric Association

1981 American Medical Association

1992-1995 West Coast College of Biological Psychiatry

1992-1995 The American Academy of Clinical Psychiatrists

2007-2012 Schizophrenia International Research Society

Elected Offices

2009-2012 Southern California Psychiatric Society, Representative

2013-2014 Southern California Psychiatric Society, President Elect

Major Research Interests

The clinical genetics and pathophysiology of Schizophrenia and Schizophrenia Spectrum Disorders; past medical director of a study of two hundred schizophrenic patients and their first degree relatives as part of a large collaborative research effort.

Psychopharmacologic treatment of mood, anxiety and schizophrenic disorders.

Teaching Experience

1977-1978 Supervised clinical work in medicine of Tufts University medical students at Faulkner Hospital

1979-1981 Organized Psychopharmacology Seminars for Department of Medicine, Wadsworth Hospital, Los Angeles, CA

1979-1981 Supervised clinical work in inpatient psychiatry of UCLA medical students and psychiatry residents, Neuropsychiatric Institute, UCLA, Los Angeles, CA

1982-Present Supervised and lectured psychiatry residents, psychology interns, and medical students, in the outpatient department of the Neuropsychiatric Institute, UCLA, Los Angeles, CA

1983-Present Numerous public speaking engagements at hospitals, universities and clinics on various topics in psychopharmacology and the pathophysiology of schizophrenia.

1983-2012 International speaker for Pfizer and Bristol-Myers-Squibb; National speaker for Ciba-Geigy, Pfizer, Searle, Lilly, Glaxo-Burroughs-Wellcome, Bristol-Myers Squibb, Wyeth and Abbott Laboratories; regional speaker for Pfizer, Dista, Sandoz Pharmaceuticals, Searle, UpJohn, Bristol-Myers-Squibb, and Mead Johnson; local speaker for Organon, Astra-Zeneca, and Parke-Davis

1984-1995 Coordinate and help run anxiety and mood disorders seminars for UCLA psychiatry residents and psychology interns.

1985 Chaired an Anxiety Disorders Symposium sponsored by Wyeth Laboratories

1995-2010 Present Advanced Psychopharmacology lectures to UCLA Psychiatry Residents

1996-Present Chair a journal club for UCLA psychiatry faculty

Principal Clinical and Hospital Service Responsibilities:

1981-1982 Psychiatrist in Charge, Bowditch Hall Clinical Research Unit, McLean Hospital, Belmont, MA

1982-1987 Assistant Director, UCLA Outpatient Psychiatry Department, Los Angeles, CA

1982-1983 Assistant Director, UCLA Affective Disorders Clinic, Los Angeles,CA

1983-1987 Director, Outpatient Psychopharmacology, Neuropsychiatric Institute, UCLA, Los Angeles, CA

1984-1987 Director, Anxiety Disorder Treatment Program, Neuropsychiatric Institute, UCLA, Los Angeles, CA

1984-2011 Medical Director for the UCLA Family Study of Schizophrenia

1988-1992 Director, Intensive Care Unit, Westwood Hospital, Los Angeles, CA

1988-2003 President, Pacific Psychopharmacology Research Institute, Santa Monica, CA

Media Experience

1982-Present Numerous radio and television interviews

1986 Co-wrote and moderated two Art Ulene productions for ABC: “Panic Disorder” and “Obsessive-Compulsive Disorder”.

1986 Wrote and moderated two C.M.E. network video productions: “The Pharmacokinetics of Benzodiazepines” and “Panic Disorder”

1987 CME Network: “Obsessive Compulsive Disorder”

1988 Interview on KTWV radio about the holiday blues and seasonal depression

2000 Web-casting, lectures from the UCLA Web studio on psychopharmacology

Reviewer For:

Editor of Efocus, the continuing medical education electronic journal of the APA 2012-present

American Journal of Psychiatry (1982-present)

Journal of Clinical Psychopharmacology (1988-present)

Brain and Behavior (2014-present)

Journal of Neuropsychiatry and Clinical Neurosciences (1996-present)

American Psychiatric Association “Practical Guidelines” Series (Fall 1991)

Consultant for American Psychiatric Association Practice Guidelines for Eating Disorders, American Journal of Psychiatry, Vol. 150, No. 2, Feb. 1993, p. 207-288

Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry 151:12, Dec. 1994 Supplement

Schizophrenia Research (2007-present)

Consultant for American Psychiatric Association Practice Guidelines for the Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry; 2009 Edition.

Bibliography

Journals

Fogelson, D.L.; Marder, S.R.; Van Putten, T.: “Dialysis for Schizophrenia: Review of Clinical Trials and Implications for Further Research”, Am J Psychiatry, 137:605-607, 1980.

Fogelson, D.L.; Cohen, B.M.; Pope, Jr., H.G.: “DSM III Schizophreniform Disorder”, Am J Psychiatry, 139:1281-1285, 1982.

Arana, G.W.; Berreira, P.J.; Cohen, B.M.; Lipinski, J.F.; Fogelson, D.L.: “The Dexamethasone Suppression Test in Psychotic Disorders”, Am J Psychiatry, 140:1521-1523, 1983.

Nuechterlein, K.H.; Snyder, K.; Dawson, M.; Rappe, S.; Gitlin, M.; Fogelson, D.L.: “Expressed Emotion, Fixed Dose Fluphenazine Treatment, and Relapse in Recent-Onset Schizophrenia”, Psychopharmacology Bulletin, 22(3):633-639, 1986.

Gitlin, M.J.; Midha, K.K.; Fogelson, D.L.; Nuechterlein, K.H.: “Persistence of Fluphenazine in Plasma After Decanoate Withdrawal”, J. Clin Psychopharmacol, 8(1):53-56, 1988.

Fogelson, D.L.; Bystritsky, A.; Sussman, N.: “Inter-Relationships Between Major Depression and the Anxiety Disorders: Clinical Relevance”, Psychiatric Annals, 18(3):158-167, 1988.

Nuechterlein, K.H.; Dawson, M.; Ventura, J.; Fogelson, D.L.; Gitlin, M.; Mintz, J.: “Testing Vulnerability Models: Stability of Potential Vulnerability Indicators Across Clinical State”, In H. Haefner and W.F. Gattaz (Eds.) Search for the Causes of Schizophrenia, Vol. 2. Springer-Verlag Berlin Heidelberg, 1990.

Clomipramine Study Group (Fogelson, D.L., member of group): “Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder”, Arch Gen Psychiatry, 48(8):730-738, 1991.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Subotnik, K.; Talovic, S.A.: “Interrater Reliability of the Structured Clinical Interview for DSM-III-R, Axis II: Schizophrenia Spectrum and Affective Spectrum Disorders”, Psych Research, 39:55-63, 1991.

Fogelson, D.L.; Bystritsky, A.: “Imipramine in the Treatment of Obsessive Compulsive Disorder With and Without Major Depression”, Annals of Clin. Psychiatry, 3(3):233-237, 1991.

Fogelson, D.L.; Jacobson, S.; Sternbach, H.: “A Retrospective Study of Valproate in Private Practice”, Annals of Clin. Psychiatry, 3(4):315-320, 1991.

Fogelson, D.L., Epitome: Obsessive Compulsive Disorder, The Western Journal of Medicine, 155(5):522, 1991.

Goldstein, M.J.; Talovic, S.A.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Asarnow, R.F.: “Family Interaction Versus Individual Psychopathology: Do They Indicate the Same Processes in the Families of Schizophrenics?”, British Journal of Psychiatry, Suppl., 161(18):97-102, 1992.

Bystritsky, A.; Fogelson, D.L.; Doctor, R.; Yager, J.: “Symptom Differences Among Anxiety Patients in Clinics with Differing Treatment Orientations: A Pilot Investigation”, J. Psychotherapy, 2(2), Spring 1993.

Fogelson, D.L.; Bystritsky, A.; Pasnau, R.: “Bupropion in the Treatment of Bipolar Disorders: The Same Old Story?”, J. Clinical Psychiatry, 53:443-446, 1992.

Subotnik, K.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Talovic, S.A.: “Depressive Symptoms in the Early Course of Schizophrenia: Relationship to Familial Psychiatric Illness”, Am J Psych, 151(11):1551-1556, 1997.

Gitlin, M.; Nuechterlein, K.H.; Mintz, J.; Fogelson, D.L.; Bartzokis, G.; Aravagiri, M.: “Fluphenazine Levels During Maintenance Treatment of Recent Onset Schizophrenia: Relation to Side Effects, Psychosocial Function and Depression”, Psychopharmacology 148:350-354, 2000.

Fogelson, D.L., Nuechterlein, K.H.H., Asarnow, R.F.F., Payne, D.L., Subotnik, K.L, Giannini, C.: “The Factor Structure of Schizophrenia Spectrum Signs and Symptoms in First-Degree Relatives of Schizophrenic Patients from the UCLA Family Members Study”, Psychiatry Research 87:137-146, 1999.

Asarnow, R.F., Nuechterlein, K.H., Fogelson, D.L., Subotnik, K.L., Payne, D.L., Russell, AT., Asamen, J., Kuppinger, H., Kendler, K.S., Schizophrenia and Schizophrenia Spectrum Personality Disorders in the First-Degree Relatives of Children with Schizophrenia: The UCLA Family Members Study, Arch of General Psychiatry, 58:581-588, 2001.

Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, Bartzokis G, Aravagiri M, Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry, 158(11):1835-42, 2001.

Asarnow R, Nuechterlein K, Asamen J, Fogelson DL, Subotnik KL, Zaucha K, Guthrie D: Neurocognitive functioning and schizophrenia spectrum disorders can be independent expressions of familial liability for schizophrenia in community control children: the UCLA family study, Schizophrenia Research. 54:111-120, 2002.

Neuchterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Payne DL, Kendler KS, Neale MC, Jacobson KC, Mintz J: The Structure of Schizotypy: Relationships Between Neurocognitive and Personality Disorder Features in Relatives of Schizophrenic Patients in the UCLA Family Study. Schizophrenia Research, 54:121-130, 2002.

Asarnow RF, Nuechterlein KH, Subotnik KL, Fogelson DL, Torquato RD, Payne DL, Asamen J, Mintz J, Guthrie D: Neurocognitive Impairments in Non-psychotic Parents of Children with Schizophrenia and Attention Deficit Disorder: The UCLA Family Study. Arch of General Psychiatry, 59:1053-1060, 2002.

Fogelson DL, Nuechterlein KH, Asarnow RF, Payne DL, Subotnik KL. Validity of the family history method for diagnosing schizophrenia, schizophrenia-related psychoses, and schizophrenia-spectrum personality disorders in first-degree relatives of schizophrenia probands. Schizophr Res, 68:309-17, 2004.

Subotnik KL, Asarnow RF, Nuechterlein KH, Fogelson DL, Thorpe TI, Payne DL, Giannini CA, Kuppinger HE, Torquato RD, Mintz J, Hwang SS, Gottesman II. MMPI vulnerability indicators for schizophrenia and attention deficit disorder: UCLA family study of biological parents of offspring with childhood-onset schizophrenia or ADHD. Behav Genet., 35(2):159-75, 2005.

Fogelson DL, Nuechterlein KH, Asarnow RA, Payne DL, Subotnik KL, Jacobson KC, Neale MC, Kendler KS: Avoidant personality disorder is a separable schizophrenia-spectrum personality disorder even when controlling for the presence of paranoid and schizotypal personality disorders The UCLA family study. Schizophr Res, 91:192-9, 2007.

Fogelson DL, Asarnow RA, Sugar CA, Subotnik KL, Jacobson KC, Neale MC, Kendler KS, Kuppinger H, Nuechterlein KH. Avoidant personality disorder symptoms in first-degree relatives of schizophrenia patients predict performance on neurocognitive measures: The UCLA family study. Schizophr Res, 2010 Jan 4, Ahead of Print.

Letters

Fogelson, D.L.: “Using Carbamazepine Effectively”, Am J Psychiatry, 141:1130, 1984.

Fogelson, D.L.: “Lorazepam and Oxazepam in the Treatment of Panic Disorder”. J. Clin Psychopharmacology, 8(2):150-151,1988.

Fogelson, D.L.: “Weight Gain During Fluoxetine Treatment”, J. Clin Psychopharmacology, 11(3):220, 1991.

Fogelson, D.L.: “Nefazodone and/or Sodium Tetradecyl Sulfate Associated Leukopenia, Fever and Shaking Chills in a Patient with Premenstrual Dysphoric Disorder”, J. Clin Psychopharmacology, 17(3):222-223, 1997.

Fogelson, D.L.; Sternbach, H.: “Lamotrigine Treatment of Refractory Bipolar Disorder”, J. Clin Psychiatry, 58(6):271-273, 1997.

Fogelson, D.L.: “Fenfluramine and the Cytochrome”, P450 System. Am. J. Psychiatry, 154(3):436-437, 1997.

Fogelson, D.L.; Sternbach, H.; Payne, D.: “A Naturalistic Pilot Study Comparing Haloperidol, Clozapine, Sertindole, and Risperidone in Partially Responsive Chronic Schizophrenia or Schizoaffective Disorder”, J Clin Psychopharmacology, 17(6):492-494, 1997.

Abstracts

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Mintz, J.: “Depressive Symptoms in Recent-Onset Schizophrenia Patients Are Associated With a Family History of Depression”. Presented at theAmerican Psychiatric Association annual meeting. May 21, 1997, San Diego, CA.

Nuechterlein, K.H.; Subotnik, K.L.; Asarnow, R.F.; Gottesman, I.; Fogelson, D.L.; Payne, D.L.; Torquato, R.D.: “MMPI Profiles of First-Degree Relatives of Recent-Onset Schizophrenia Probands”. Presented at the International Congress on Schizophrenia Research 1997.

Asarnow, R.F.; Nuechterlein, K.H.; Torquato, R.D.; Subotnik, K.L.; Fogelson,D.L.: “Cognitive/Neuropsychological Abnormalities in the Parents of Children with a Schizophrenic Disorder”. Presented at the International Congress on Schizophrenia Research 1997.

Subotnik, K.L.; Asarnow, R.F.; Nuechterlein, K.H.; Payne, D.L.; Fogelson, D.L.; Gottesman, I.I.: “MMPI Differences Among First-Degree Relatives of Probands with Childhood-Onset Schizophrenia, Attention Deficit Disorder, and Normal Control Children”. Presented at the International Congress on Schizophrenia Research 1997.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.L.; Subotnik, K.L.; Giannini, C.: “The Factor Structure of Schizophrenia Spectrum signs and Family Members Study”. Presented at the International Congress on Schizophrenia Research 1997.

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Goldstein, M.J., Fogelson, D.L.; Richard D. Torquato: “Communication Deviance is Associated with Putative Genetic Vulnerability Indicators in Relatives of Schizophrenia Patients”. Presented at the International Congress on Schizophrenia Research, 1999.

Fogelson, D.L.; Torquato, R.D.; Asarnow, R.F.; Subotnik, K.L.: “Are Categorical or Dimensional Approaches to Personality Disorders Better for Discriminating the Biological Parents of Probands with Childhood-Onset Schizophrenia Versus ADD”. Presented at the International Congress on Schizophrenia Research, 1999.

Nuechterlein, K.H.; Subotnik, K.L.; Gitlin, M.; Dawson, M.E.; Ventura, J.; Snyder, K.S.; Fogelson, D.L.; Shaw, S.; Mintz, J.: “Neurocognitive and Environmental Contributors to Work Recovery After Initial Onset of Schizophrenia: Answers from Path Analyses”. Presented at the International Congress on Schizophrenia Research, 1999.

Payne, D.L.; Kuppinger, H.E.; Asarnow, R.F.; Subotnik, K.L.; Fogelson, D.L.; Nuechterlein, K.H.: “Examination of Wisconsin Psychosis-Proneness Scales as an Indication of Familial Vulnerability to Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 1999.

Asarnow, R.F.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Torquato, R.D.; Payne, D.L.; Kuppinger, H.E.: “Defining the Boundaries of the Schizophrenia Phenotype: The UCLA Family Study”. Presented at the International Congress on Schizophrenia Research, 1999.

Subotnik, K.L.; Asarnow, R.F.; Fogelson, D.L.; Gottesman, I.I.; Thorpe, T.; Payne, D.L.; Giannini, C.; Torquato, R.; Kuppinger, H.E.; Nuechterlein, K.H.: “MMPI Vulnerability Indicators for Schizophrenia: Findings from the UCLA Family Study Examining Biological Parents of Children with Schizophrenia or Attention Deficit Disorder and Parents of Community Controls”. Presented at the 2nd International Conference on Early Psychosis March 31, 2000. New York.

Asarnow, R.F.; Nuechterlein, K.H.; Subotnik, K.L.; Fogelson, D.L.; Torquato, R.D.; Payne, D.L.; Guthrie, D.: “Specificity of Neurocognitive Impairments in Parents of Probands with Childhood Onset of Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 2001.

Subotnik, K.L.; Nuechterlein, K.H.; Gitlin, M.; Siegel, B.; Bartzokis, G.; Fogelson, D.L.; Ventura, J.: “First Episode Patients Treated With Risperidone Show Better Neurocognitive and Functional Outcome Than Patients Treated with Fluphenazine Decanoate”. Presented at the International Congress on Schizophrenia Research, 2001.

Nuechterlein, K.H.; Asarnow, R.F.; Jacobson, K.; Subotnik, K.L.; Neale, M.; Fogelson, D.L.; Kendler, K.: “Neurocognitive Vulnerability Factors in First-Degree Relatives of Schizophrenic Probands Show Accelerated Aging Effects”. Presented at the International Congress on Schizophrenia Research, 2001.

Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; Gitlin, M.J.; Fogelson, D.L.; Bartzokis, G.; Subotnik, K.L.: “Rates of Smoking in Recent-onset Schizophrenia Patients Receiving Traditional Versus Atypical Antipsychotic Medications”. Presented at the International Congress on Schizophrenia Research, 2001.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.; Subotnik, K.L.; Kuppinger, H.: “Validity of the Family History Method for Diagnosing Schizophrenia and Schizophrenia related Psychoses in First-Degree Relatives of Schizophrenic Probands”. Presented at the International Congress on Schizophrenia Research, 2001.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.: “Avoidant Personality Disorder Increases the Detection of First Degree Relatives Affected by a Schizophrenia Spectrum Diagnosis”. Accepted to the International Congress on Schizophrenia Research, 2003.

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Payne, D.L.; Ventura, J.; Kendler, K.S.:”Relationship between positive and negative symptoms of schizophrenia and dimensions of personality pathology in biological parents”. Accepted to the International Congress on Schizophrenia Research, 2003.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.; Sugar, C.: “Avoidant Personality Disorder Symptoms in First-Degree Relatives of Schizophrenics Predict Performance on Neurocognitive Measures The UCLA Family Study”. Presented at the International Congress on Schizoprhenia Research, 2009

Research

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein, M.J.; Mintz, J.: “Depressive Symptoms in Recent-Onset Schizophrenia Patients Are Associated With a Family History of Depression”. Presented at theAmerican Psychiatric Association annual meeting. May 21, 1997, San Diego, CA.

Nuechterlein, K.H.; Subotnik, K.L.; Asarnow, R.F.; Gottesman, I.; Fogelson, D.L.; Payne, D.L.; Torquato, R.D.: “MMPI Profiles of First-Degree Relatives of Recent-Onset Schizophrenia Probands”. Presented at the International Congress on Schizophrenia Research 1997.

Asarnow, R.F.; Nuechterlein, K.H.; Torquato, R.D.; Subotnik, K.L.; Fogelson,D.L.: “Cognitive/Neuropsychological Abnormalities in the Parents of Children with a Schizophrenic Disorder”. Presented at the International Congress on Schizophrenia Research 1997.

Subotnik, K.L.; Asarnow, R.F.; Nuechterlein, K.H.; Payne, D.L.; Fogelson, D.L.; Gottesman, I.I.: “MMPI Differences Among First-Degree Relatives of Probands with Childhood-Onset Schizophrenia, Attention Deficit Disorder, and Normal Control Children”. Presented at the International Congress on Schizophrenia Research 1997.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.L.; Subotnik, K.L.; Giannini, C.: “The Factor Structure of Schizophrenia Spectrum signs and Family Members Study”. Presented at the International Congress on Schizophrenia Research 1997.

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Goldstein, M.J., Fogelson, D.L.; Richard D. Torquato: “Communication Deviance is Associated with Putative Genetic Vulnerability Indicators in Relatives of Schizophrenia Patients”. Presented at the International Congress on Schizophrenia Research, 1999.

Fogelson, D.L.; Torquato, R.D.; Asarnow, R.F.; Subotnik, K.L.: “Are Categorical or Dimensional Approaches to Personality Disorders Better for Discriminating the Biological Parents of Probands with Childhood-Onset Schizophrenia Versus ADD”. Presented at the International Congress on Schizophrenia Research, 1999.

Nuechterlein, K.H.; Subotnik, K.L.; Gitlin, M.; Dawson, M.E.; Ventura, J.; Snyder, K.S.; Fogelson, D.L.; Shaw, S.; Mintz, J.: “Neurocognitive and Environmental Contributors to Work Recovery After Initial Onset of Schizophrenia: Answers from Path Analyses”. Presented at the International Congress on Schizophrenia Research, 1999.

Payne, D.L.; Kuppinger, H.E.; Asarnow, R.F.; Subotnik, K.L.; Fogelson, D.L.; Nuechterlein, K.H.: “Examination of Wisconsin Psychosis-Proneness Scales as an Indication of Familial Vulnerability to Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 1999.

Asarnow, R.F.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Torquato, R.D.; Payne, D.L.; Kuppinger, H.E.: “Defining the Boundaries of the Schizophrenia Phenotype: The UCLA Family Study”. Presented at the International Congress on Schizophrenia Research, 1999.

Subotnik, K.L.; Asarnow, R.F.; Fogelson, D.L.; Gottesman, I.I.; Thorpe, T.; Payne, D.L.; Giannini, C.; Torquato, R.; Kuppinger, H.E.; Nuechterlein, K.H.: “MMPI Vulnerability Indicators for Schizophrenia: Findings from the UCLA Family Study Examining Biological Parents of Children with Schizophrenia or Attention Deficit Disorder and Parents of Community Controls”. Presented at the 2nd International Conference on Early Psychosis March 31, 2000. New York.

Asarnow, R.F.; Nuechterlein, K.H.; Subotnik, K.L.; Fogelson, D.L.; Torquato, R.D.; Payne, D.L.; Guthrie, D.: “Specificity of Neurocognitive Impairments in Parents of Probands with Childhood Onset of Schizophrenia”. Presented at the International Congress on Schizophrenia Research, 2001.

Subotnik, K.L.; Nuechterlein, K.H.; Gitlin, M.; Siegel, B.; Bartzokis, G.; Fogelson, D.L.; Ventura, J.: “First Episode Patients Treated With Risperidone Show Better Neurocognitive and Functional Outcome Than Patients Treated with Fluphenazine Decanoate”. Presented at the International Congress on Schizophrenia Research, 2001.

Nuechterlein, K.H.; Asarnow, R.F.; Jacobson, K.; Subotnik, K.L.; Neale, M.; Fogelson, D.L.; Kendler, K.: “Neurocognitive Vulnerability Factors in First-Degree Relatives of Schizophrenic Probands Show Accelerated Aging Effects”. Presented at the International Congress on Schizophrenia Research, 2001.

Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; Gitlin, M.J.; Fogelson, D.L.; Bartzokis, G.; Subotnik, K.L.: “Rates of Smoking in Recent-onset Schizophrenia Patients Receiving Traditional Versus Atypical Antipsychotic Medications”. Presented at the International Congress on Schizophrenia Research, 2001.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.; Subotnik, K.L.; Kuppinger, H.: “Validity of the Family History Method for Diagnosing Schizophrenia and Schizophrenia related Psychoses in First-Degree Relatives of Schizophrenic Probands”. Presented at the International Congress on Schizophrenia Research, 2001.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.: “Avoidant Personality Disorder Increases the Detection of First Degree Relatives Affected by a Schizophrenia Spectrum Diagnosis”. Accepted to the International Congress on Schizophrenia Research, 2003.

Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Payne, D.L.; Ventura, J.; Kendler, K.S.:”Relationship between positive and negative symptoms of schizophrenia and dimensions of personality pathology in biological parents”. Accepted to the International Congress on Schizophrenia Research, 2003.

Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.; Jacobson, K.C.; Neale, M.C.; Kendler, K.S.; Sugar, C.: “Avoidant Personality Disorder Symptoms in First-Degree Relatives of Schizophrenics Predict Performance on Neurocognitive Measures The UCLA Family Study”. Presented at the International Congress on Schizoprhenia Research, 2009